Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Chardan Healthcare Acquisition 2 Corp (CHAQ)

Chardan Healthcare Acquisition 2 Corp (CHAQ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 90,643
  • Shares Outstanding, K 10,778
  • Annual Sales, $ 0 K
  • Annual Income, $ -780 K
  • 60-Month Beta 0.05
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade CHAQ with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.06 +4.34%
on 09/02/21
10.52 -20.06%
on 08/30/21
-1.68 (-16.65%)
since 08/02/21
3-Month
8.06 +4.34%
on 09/02/21
10.52 -20.06%
on 08/30/21
-1.65 (-16.36%)
since 06/02/21
52-Week
8.06 +4.34%
on 09/02/21
11.12 -24.37%
on 02/01/21
-1.39 (-14.18%)
since 09/02/20

Most Recent Stories

More News
Renovacor, Inc. Closes Its Business Combination with Chardan Healthcare Acquisition 2 Corp. and Will Begin Trading on the New York Stock Exchange

Renovacor, Inc. (“Renovacor”), an early‑stage biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system diseases...

CHAQ : 8.41 (-10.15%)
Renovacor Announces the Appointment of Elizabeth White, Ph.D., as Chief Business Officer and Senior Vice President of Operations

Dr. White is an industry leader with over three decades of pharmaceutical experience in business management and strategy with a focus on rare diseases and gene therapies

CHAQ : 8.41 (-10.15%)
Renovacor Announces the Appointment of Jiwen Zhang, Ph.D., as Senior Vice President, Regulatory Affairs and Quality Assurance

Dr. Zhang has over 20 years of experience in regulatory affairs, with over a decade specifically in the field of cell and gene therapy

CHAQ : 8.41 (-10.15%)
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Reminds Investors of Investigation of PACX, CHAQ, FMBI, and FST Mergers

WILMINGTON, Del., July 02, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating:

PACX : 10.20 (unch)
CHAQ : 8.41 (-10.15%)
FMBI : 21.51 (+2.77%)
FST : 10.18 (+0.30%)
Renovacor Announces the Appointments of Joan Lau, Ph.D., and Gregory F. Covino to its Board of Directors

Appointments to be effective upon closing of the previously announced merger between Renovacor and Chardan Healthcare Acquisition 2 Corp.

CHAQ : 8.41 (-10.15%)
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Chardan Healthcare Acquisition 2 Corp. Merger

WILMINGTON, Del., June 07, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating Chardan Healthcare Acquisition 2 Corp. (“Chardan Healthcare”) (NYSE: CHAQ ) regarding...

CHAQ : 8.41 (-10.15%)
Renovacor Announces the Appointment of Marc Semigran, M.D., as Chief Medical Officer

Former chief medical officer of MyoKardia to lead clinical development at Renovacor

CHAQ : 8.41 (-10.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Chardan Healthcare Acquisition 2 Corp. entered into a definitive business combination agreement with Renovacor Inc.

See More

Key Turning Points

3rd Resistance Point 10.44
2nd Resistance Point 9.90
1st Resistance Point 9.15
Last Price 8.41
1st Support Level 7.86
2nd Support Level 7.32
3rd Support Level 6.57

See More

52-Week High 11.12
Fibonacci 61.8% 9.95
Fibonacci 50% 9.59
Fibonacci 38.2% 9.23
Last Price 8.41
52-Week Low 8.06

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar